查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088837

抗精神病藥物市場：2026-2032年全球市場預測（依藥物類別、適應症、治療分類、給藥途徑及分銷管道分類）

Antipsychotic Drugs Market by Drug Type, Disease Indication, Therapeutic Class, Route of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗精神病藥物市場規模將成長至 271.6 億美元，年複合成長率為 8.29%。

主要市場統計數據
基準年 2025 155.5億美元
預計年份：2026年 168.1億美元
預測年份 2032 271.6億美元
複合年成長率 (%) 8.29%

抗精神病藥物市場的需求主要受持續存在的臨床負擔所驅動，包括思覺失調症、躁鬱症、急性精神病和重度憂鬱症的輔助性治療需求。根據世界衛生組織（WHO）估計，全球約有2400萬人患有思覺失調症，約有4000萬人患有雙相情感障礙，這使得人們對有效、耐受性好且易於獲得的抗精神病藥物的需求持續存在。

市場發展動能主要受以下因素影響：第二代抗精神病藥物的持續使用、學名藥的廣泛普及，以及旨在解決因用藥依從性差而導致的複發問題的長效注射型抗精神病藥物的日益普及。同時， 食品藥物管理局於2024年批准了zanomeline和托吡氯銨用於治療思覺失調症，這表明人們對非多巴胺能機制的興趣重新燃起，競爭格局也正在超越傳統的多巴胺D2受體調節框架。

抗精神病藥物治療模式的變革性變化

治療方法正從單純抑制症狀轉向預防復發、功能恢復和個人化安全管理。長效注射藥物的臨床意義日益凸顯，因為復發、住院和治療中斷仍然是思覺失調症治療的主要成本因素。醫療保健系統擴大從治療總成本的角度評估抗精神病藥物治療，而不僅僅是從單位成本的角度。

人工智慧對抗精神病藥物的累積影響

人工智慧正在對抗精神病藥物的發現、臨床開發、藥物安全監測和商業策略等各個領域產生累積影響。在藥物發現階段，人工智慧驅動的建模被用於化合物篩檢、受體結合譜預測以及早期識別安全風險因子。在臨床開發階段，機器學習可以輔助進行臨床試驗中心選擇、患者分層、復發風險預測以及思覺失調症和雙相情感障礙臨床試驗中複雜終點的分析。

關鍵區域視野下的全球抗精神病藥物需求

北美地區仍然是抗精神病藥物的主要市場，這得益於其較高的診斷率、先進的精神衛生保健基礎設施、廣泛的保險覆蓋範圍以及創新療法的快速普及。尤其值得一提的是，美國擁有舉足輕重的地位，因為FDA的批准、為實現精神衛生保健服務的平等獲取所做的努力以及專科醫生的處方模式，往往決定著全球市場新藥上市的順序。在加拿大，公共藥物福利和系統化的精神健康服務支撐著市場需求，但報銷評估可能會影響藥物的取得速度。

針對特定群體的抗精神病藥物商業策略的關鍵見解

在東協地區，全民健康覆蓋（UHC）計劃的擴展、都市區醫院網路的建設以及對嚴重精神疾病認知的提高，都推動了對抗精神病藥物的需求，但高所得成員國和低收入成員國在藥物獲取方面存在顯著差異。海灣合作理事會（GCC）國家已將精神健康納入其國家醫療改革議程的優先事項，在已建立報銷機制的地區，品牌藥物和以醫院為基礎的專科護理具有巨大的發展潛力。

來自抗精神病藥物市場主要國家的見解

美國是全球最具商業性影響力的國家，這得益於其高昂的藥品支出、廣泛的專科醫療服務以及美國食品藥物管理局（FDA）針對思覺失調症新療法的明確核准流程。加拿大憑藉著公共健保體系，提供了穩定的需求。墨西哥和巴西是重要的拉丁美洲市場，這兩個國家的藥品取得依賴公共採購、私人保險以及學名藥的價格。在英國，國家醫療服務體系（NHS）的處方和成本效益評估影響藥物的採納。同時，德國和法國憑藉其完善的醫保體系和龐大的病患目標人口，仍是重要的歐洲市場。

為抗精神病藥物行業的領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，例如復發預防、藥物依從性、安全性和生活品質 (QOL)。長效注射劑、代謝特性較佳的療法、能減少多巴胺相關副作用的作用機制，應繼續成為研發和生命週期管理的重中之重。各機構也應投資於能夠證明降低住院率、急診就診率和治療中斷率的證據包。

抗精神病藥物市場情報調查方法

本執行摘要基於系統性的研究途徑，結合了檢驗的二手研究、監管資訊、臨床證據審查和市場三角驗證。主要資訊來源來自國家監管機構（如世界衛生組織 (WHO)、美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA)）的公開資訊、臨床試驗註冊資料、同行評審的精神病學文獻、藥品附加檔、保險報銷資訊、治療指南和公共衛生資料集。

結論：抗精神病藥物市場前景

抗精神病藥物市場正進入一個新階段，其特點是：非典型療法已被廣泛應用，長效注射劑的使用日益增多，以及治療思覺失調症的新作用機制不斷湧現。全球嚴重精神疾病的負擔持續支撐著市場需求，但同時，保險公司日益嚴格的審查也要求提供更有力的證據，證明藥物在安全性、依從性、復發預防以及降低總治療成本方面的優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 抗精神病藥物市場：依藥物類型分類

  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • 布瑞西普拉唑
  • 棕櫚酸帕利哌酮
  • Haloperidol
  • 氯氮平
  • 齊拉西酮
  • Lurasidone

第8章：抗精神病藥物市場：依疾病適應症分類

  • 思覺失調症
  • 躁鬱症
  • 單相憂鬱症
  • 失智症相關精神病

第9章：抗精神病藥物市場：依治療分類

  • 第一代抗精神病藥物
  • 第二代抗精神病藥物
  • 第三代

第10章：抗精神病藥物市場：依給藥途徑分類

  • 口服
  • 腸外
  • 經皮給藥

第11章：抗精神病藥物市場：按分銷管道分類

  • 線上
  • 離線

第12章 抗精神病藥物市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：抗精神病藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 抗精神病藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Alkermes, Inc.
  • AstraZeneca plc
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • H. Lundbeck A/S
  • Intra-Cellular Therapies, Inc.
  • Johnson & Johnson
  • Karuna Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novartis International AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.
Product Code: MRR-AD36CD897CDF

The Antipsychotic Drugs Market is projected to grow by USD 27.16 billion at a CAGR of 8.29% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.55 billion
Estimated Year [2026] USD 16.81 billion
Forecast Year [2032] USD 27.16 billion
CAGR (%) 8.29%

The antipsychotic drugs market is anchored by the persistent clinical burden of schizophrenia, bipolar disorder, acute psychosis, and adjunctive treatment needs in major depressive disorder. The World Health Organization estimates that schizophrenia affects about 24 million people globally, while bipolar disorder affects around 40 million people, creating sustained demand for effective, tolerable, and accessible psychosis therapeutics.

Market momentum is being shaped by continued use of second-generation antipsychotics, broad generic availability, and rising adoption of long-acting injectable antipsychotics designed to address relapse linked to poor adherence. At the same time, the 2024 U.S. FDA approval of xanomeline and trospium chloride for schizophrenia signaled renewed interest in non-dopamine mechanisms, expanding the competitive landscape beyond traditional dopamine D2 receptor modulation.

Transformative Shifts in the Antipsychotic Treatment Landscape

The landscape is shifting from symptom suppression alone toward relapse prevention, functional recovery, and personalized safety management. Long-acting injectables are gaining clinical relevance because relapse, hospitalization, and treatment discontinuation remain major cost drivers in schizophrenia care. Health systems are increasingly evaluating antipsychotic therapies through total cost of care, not only unit price.

Scientific innovation is also changing competitive positioning. Established atypical antipsychotics continue to dominate prescribing due to familiarity and generic access, but new mechanisms involving muscarinic receptors, TAAR1 pathways, glutamatergic modulation, and adjunctive digital adherence tools are reshaping research priorities. Regulatory expectations around metabolic risk, extrapyramidal symptoms, sedation, cardiovascular safety, and real-world evidence are becoming central to product differentiation.

Cumulative Impact of Artificial Intelligence on Antipsychotic Drugs

Artificial intelligence is having a cumulative impact across antipsychotic drug discovery, clinical development, pharmacovigilance, and commercial strategy. In discovery, AI-enabled modeling is being used to screen compounds, predict receptor-binding profiles, and identify safety liabilities earlier. In clinical development, machine learning can support site selection, patient stratification, relapse-risk prediction, and analysis of complex endpoints in schizophrenia and bipolar disorder trials.

The strongest near-term value is likely to come from practical applications such as adverse-event signal detection, medication adherence analytics, and precision prescribing support. However, AI tools must be validated against diverse patient populations because psychosis care is highly sensitive to bias, privacy risk, and social determinants of health. Organizations that combine AI with regulated evidence standards will be better positioned to improve antipsychotic therapy outcomes.

Key Regional Insights Across Global Antipsychotic Demand

North America remains a leading region for antipsychotic drugs due to high diagnosis rates, advanced psychiatric care infrastructure, payer coverage, and rapid uptake of innovative therapies. The United States is especially influential because FDA approvals, mental health parity initiatives, and specialist prescribing patterns often shape global launch sequencing. Canada supports demand through public drug plans and structured mental health services, although reimbursement assessments can influence speed of access.

Europe is characterized by mature prescribing, strong pharmacovigilance, and cost-containment policies across national health systems. The European Union emphasizes health technology assessment, real-world evidence, and equitable access, while the United Kingdom, Germany, France, Italy, and Spain each balance innovation with generic substitution and budget control. Asia-Pacific is expanding through rising mental health awareness, increasing psychiatric service capacity, and large patient pools in China, India, Japan, South Korea, and Australia.

Latin America shows growing demand led by Brazil and Mexico, but access variability, public-sector procurement cycles, and affordability barriers remain important. The Middle East, particularly GCC markets, is investing in specialty care and hospital infrastructure, while Africa continues to face a large treatment gap due to limited psychiatric workforce, medicine availability, and financing constraints, consistent with WHO findings that many low- and middle-income settings have limited access to mental health services and essential psychotropic medicines.

Key Group Insights for Antipsychotic Drug Commercial Strategy

Within ASEAN, antipsychotic demand is supported by expanding universal health coverage programs, urban hospital networks, and increasing recognition of severe mental illness, although access differs sharply between higher-income and lower-income member states. GCC countries are prioritizing mental health under national healthcare transformation agendas, with strong potential for branded therapies and hospital-based specialty care where reimbursement pathways are established.

The European Union represents a highly regulated and value-focused market where pharmacovigilance, health technology assessment, and generic competition shape pricing and uptake. BRICS economies contribute scale, especially through China, India, and Brazil, where large patient populations, local manufacturing, and government procurement strongly influence market structure. G7 countries remain central to innovation, reimbursement policy, and clinical guideline development, while NATO members collectively represent many advanced psychiatric care systems and defense-linked mental health priorities, including growing attention to trauma, depression, substance use, and severe mental illness among service members and veterans.

Key Country Insights in the Antipsychotic Drugs Market

The United States is the most commercially influential country due to high pharmaceutical spending, strong specialty care access, and a clear FDA pathway for novel schizophrenia treatments. Canada offers stable demand through public reimbursement systems, while Mexico and Brazil are important Latin American markets where public procurement, private insurance, and generic affordability define access. In the United Kingdom, National Health Service prescribing and cost-effectiveness reviews influence uptake, while Germany and France remain critical European markets because of structured reimbursement and large treated populations.

Italy and Spain are mature antipsychotic markets with strong generic penetration and regional budget management. Russia maintains demand through public and private channels but faces access and supply-chain complexity. China and India represent major long-term opportunities because of large populations, expanding psychiatric diagnosis, domestic manufacturing capacity, and government-led healthcare access initiatives. Japan has high standards for safety, post-marketing surveillance, and elderly care, Australia supports evidence-based access through national reimbursement, and South Korea combines advanced healthcare infrastructure with growing mental health investment.

Actionable Recommendations for Antipsychotic Industry Leaders

Industry leaders should prioritize differentiated clinical value in relapse prevention, adherence, safety, and quality-of-life outcomes. Long-acting injectables, therapies with improved metabolic profiles, and mechanisms that reduce dopamine-related adverse effects should remain high-priority development and lifecycle-management opportunities. Organizations should also invest in evidence packages that demonstrate reductions in hospitalization, emergency care utilization, and treatment discontinuation.

Commercial teams should localize access strategies by payer type, procurement model, and psychiatric infrastructure. Partnerships with community mental health providers, digital adherence platforms, and pharmacovigilance networks can strengthen real-world performance. Leaders should also build AI governance frameworks to ensure that predictive tools used in trial design, safety monitoring, or patient support meet clinical, ethical, and regulatory expectations.

Research Methodology for Antipsychotic Market Intelligence

This executive summary is built on a structured research approach combining verified secondary research, regulatory intelligence, clinical evidence review, and market triangulation. Core inputs include public information from the World Health Organization, national regulators such as the U.S. FDA and European Medicines Agency, clinical trial registries, peer-reviewed psychiatric literature, drug labels, reimbursement information, treatment guidelines, and public health datasets.

Market interpretation is developed by comparing epidemiology, treatment pathways, product approvals, patent and pipeline activity, payer behavior, pharmacovigilance requirements, and regional access conditions. Insights are validated through cross-source consistency checks and are framed to support strategic decision-making in the antipsychotic drugs market without relying on unsupported claims, market sizing, or speculative forecasts.

Conclusion: Outlook for the Antipsychotic Drugs Market

The antipsychotic drugs market is entering a new phase defined by established atypical therapies, growing use of long-acting injectables, and the emergence of novel mechanisms for schizophrenia treatment. Demand remains structurally supported by the global burden of severe mental illness, while payer scrutiny requires stronger evidence of safety, adherence, relapse prevention, and total cost-of-care benefits.

Organizations that align scientific innovation with real-world access needs will be best positioned for sustainable growth. The strongest competitive advantage will come from therapies and services that improve clinical outcomes, reduce hospitalization, support patient adherence, and address the long-standing treatment gap across both mature and emerging healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antipsychotic Drugs Market, by Drug Type

  • 7.1. Risperidone
  • 7.2. Quetiapine
  • 7.3. Olanzapine
  • 7.4. Aripiprazole
  • 7.5. Brexpiprazole
  • 7.6. Paliperidone Palmitate
  • 7.7. Haloperidol
  • 7.8. Clozapine
  • 7.9. Ziprasidone
  • 7.10. Lurasidone

8. Antipsychotic Drugs Market, by Disease Indication

  • 8.1. Schizophrenia
  • 8.2. Bipolar Disorder
  • 8.3. Unipolar Depression
  • 8.4. Dementia-related Psychosis

9. Antipsychotic Drugs Market, by Therapeutic Class

  • 9.1. First-Generation Antipsychotics
  • 9.2. Second-Generation Antipsychotics
  • 9.3. Third-Generation

10. Antipsychotic Drugs Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Transdermal

11. Antipsychotic Drugs Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Antipsychotic Drugs Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Antipsychotic Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antipsychotic Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Alkermes, Inc.
  • 16.3. AstraZeneca plc
  • 16.4. Dr. Reddy's Laboratories Ltd.
  • 16.5. Eli Lilly and Company
  • 16.6. Gedeon Richter Plc
  • 16.7. H. Lundbeck A/S
  • 16.8. Intra-Cellular Therapies, Inc.
  • 16.9. Johnson & Johnson
  • 16.10. Karuna Therapeutics, Inc.
  • 16.11. Merck & Co., Inc.
  • 16.12. Novartis AG
  • 16.13. Novartis International AG
  • 16.14. Otsuka Holdings Co., Ltd.
  • 16.15. Pfizer Inc.
  • 16.16. Roche Holding AG
  • 16.17. Sanofi S.A.
  • 16.18. Sumitomo Pharma Co., Ltd.
  • 16.19. Sun Pharmaceutical Industries Ltd.
  • 16.20. Teva Pharmaceutical Industries Ltd.
  • 16.21. Viatris Inc.
  • 16.22. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RISPERIDONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RISPERIDONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RISPERIDONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL QUETIAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL QUETIAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL QUETIAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OLANZAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OLANZAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OLANZAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARIPIPRAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARIPIPRAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARIPIPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREXPIPRAZOLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREXPIPRAZOLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREXPIPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PALIPERIDONE PALMITATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PALIPERIDONE PALMITATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PALIPERIDONE PALMITATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HALOPERIDOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HALOPERIDOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HALOPERIDOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CLOZAPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLOZAPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CLOZAPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ZIPRASIDONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ZIPRASIDONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ZIPRASIDONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LURASIDONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LURASIDONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LURASIDONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SCHIZOPHRENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIPOLAR DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UNIPOLAR DEPRESSION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UNIPOLAR DEPRESSION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UNIPOLAR DEPRESSION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DEMENTIA-RELATED PSYCHOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DEMENTIA-RELATED PSYCHOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DEMENTIA-RELATED PSYCHOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FIRST-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SECOND-GENERATION ANTIPSYCHOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THIRD-GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THIRD-GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THIRD-GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. JAPAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)